Merck Sharp Dohme Company Profile

✉ Email this page to a colleague

MERCK SHARP DOHME has twenty-three approved drugs.

There are twenty-five US patents protecting MERCK SHARP DOHME drugs.

There are six hundred and ninety patent family members on MERCK SHARP DOHME drugs in sixty-three countries and one hundred and twenty-seven supplementary protection certificates in nineteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	NOXAFIL	posaconazole	TABLET, DELAYED RELEASE;ORAL	205053-001	Nov 25, 2013	AB	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes	9,993,476	⤷ Try a Trial				⤷ Try a Trial
Merck Sharp Dohme	PREVYMIS	letermovir	TABLET;ORAL	209939-002	Nov 8, 2017		RX	Yes	Yes	8,513,255	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Merck Sharp Dohme	PREVYMIS	letermovir	SOLUTION;INTRAVENOUS	209940-001	Nov 8, 2017		RX	Yes	Yes	RE46791	⤷ Try a Trial	Y	Y		⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-004	Sep 18, 2012	7,078,381	⤷ Try a Trial
Merck Sharp Dohme	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER	famotidine	INJECTABLE;INJECTION	020249-001	Feb 18, 1994	4,283,408*PED	⤷ Try a Trial
Merck Sharp Dohme	DUTREBIS	lamivudine; raltegravir potassium	TABLET;ORAL	206510-001	Feb 6, 2015	7,820,660	⤷ Try a Trial
Merck Sharp Dohme	TEMODAR	temozolomide	CAPSULE;ORAL	021029-003	Aug 11, 1999	5,260,291*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2011-02-28
➤ Subscribe	Injection	18 mg/mL, 16.7 mL vials	➤ Subscribe	2015-11-24
➤ Subscribe	Orally Disintegrating Tablets	2.5 mg and 5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-19
➤ Subscribe	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg	➤ Subscribe	2012-11-06
➤ Subscribe	Capsules	140 mg and 180 mg	➤ Subscribe	2008-03-24
➤ Subscribe	Delayed-release Tablets	100 mg	➤ Subscribe	2014-06-16
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	25 mg, 50 mg and 100 mg	➤ Subscribe	2010-10-18
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-25

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	C01084705/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 57863 18.04.2007
1441735	C20080001	Estonia	⤷ Try a Trial	PRODUCT NAME: ISENTRESS; AUTHORISATION NO.: EMA/106827/2018; AUTHORISATION DATE: 20180222
1622880	1890019-1	Sweden	⤷ Try a Trial	PRODUCT NAME: LETERMOVIR, OR ITS SALT, SOLVATE OR SOLVATE OF ITS SALT; REG. NO/DATE: EU/1/17/1245 20180110
2576547	30/2021	Austria	⤷ Try a Trial	PRODUCT NAME: VERICIGUAT SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1561 (MITTEILUNG) 20210720
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.